A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Minnesota
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 years or above at the time of signing the informed consent form.
Histologically proven diagnosis of stage I-III invasive breast cancer.
Currently taking prescribed dose of an aromatase inhibitor (e.g., anastrazole, letrozole, exemestane) for at least 60 days with a plan to continue for at least 4 weeks after time of consent.
Initiated AI therapy must have been within 48 months at time of consent.
Experiencing AIMSS in hands and/or wrists for at least 4 weeks prior to time of consent.
Patients must have reported a score of 4 or higher on at least one of the four M-SACRAH questions regarding pain and stiffness in hands and/or wrists over the past 7 days. Patients experiencing AIMSS symptoms in other joints are eligible, but must have pain in hands and/or wrists.
Must be willing and able to comply with study visits and procedures.
Must be willing to be registered in the Minnesota Medical Cannabis Program (MMCP).
Must meet qualifications for the Minnesota Medical Cannabis
Program (MMCP). This includes:
1. Must have a qualifying condition, as per MMCP requirements, that is certified by a Health Care Practitioner.
2. Must be a Minnesota resident.
Current or planned initiation of acupuncture to arms, wrists or hands within study period.
Any known or suspected hypersensitivity to topical cannabinoids.
Any condition that the investigator believes would interfere with the ability to provide informed consent, comply with the study protocol, or would put the subject at undue risk.
You may not be if
The patient is currently using or has used cannabinoids within 4 weeks of time of consent.
Active skin lesions on hands/wrists that the investigator feels could impair absorption of cannabinoid cream or lead to increased toxicity (e.g., psoriasis, cellulitis, cutaneous lupus erythematosus, hand-foot syndrome).
Clareo Health | A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma)
